Tepoditamab
Tepoditamab (MCLA-117) is a full-length human IgG1 bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells. Tepoditamab induces upto 30-fold T-cell expansion. Tepoditamab results in moderate to strong cytokine (IFNγ, IL-6, IL-8, IL-10, and TNFα) and IFNγ release in human whole blood and PBMC, respectively. Tepoditamab can be used in acute myeloid leukaemia (AML) research[1][2][3].
Product Specifications
CAS Number
2044679-53-8
Product Name Alternative
MCLA 117
UNSPSC
12352203
Target
CD3; IFNAR; Interleukin Related; TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/tepoditamab.html
Purity
99
Solubility
10 mM in DMSO
Smiles
[Tepoditamab]
Molecular Weight
(144.787 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Ibuprofen Acyl-Beta-D-glucuronide (mixture of diastereomers)
MIR99AHG Human qPCR Primer Pair (NM_001005734)
